Surrozen, Inc. (NASDAQ:SRZNW) Short Interest Down 20.9% in January

Surrozen, Inc. (NASDAQ:SRZNW) was the recipient of a significant drop in short interest in the month of January. As of January 15th, there was short interest totaling 29,082 shares, a drop of 20.9% from the December 31st total of 36,749 shares. Based on an average daily trading volume, of 1,498 shares, the short-interest ratio is currently 19.4 days. Based on an average daily trading volume, of 1,498 shares, the short-interest ratio is currently 19.4 days.

Surrozen Trading Down 0.4%

NASDAQ:SRZNW traded down $0.00 during trading hours on Friday, reaching $0.02. 11,300 shares of the company’s stock were exchanged, compared to its average volume of 4,414. Surrozen has a 12 month low of $0.00 and a 12 month high of $0.07. The business’s 50-day simple moving average is $0.02 and its two-hundred day simple moving average is $0.02.

About Surrozen

Surrozen, Inc is a clinical-stage biotechnology company headquartered in South San Francisco, California, focused on the discovery and development of novel therapeutics that harness the Wnt signaling pathway. The company employs a proprietary “surrogate agonist” platform to engineer bispecific antibodies that mimic natural Wnt ligands by concurrently engaging Frizzled receptors and LRP5/6 co-receptors. This approach is designed to promote tissue regeneration and modulate cellular pathways implicated in fibrosis and oncology.

Surrozen’s lead program is advancing in fibrotic disease, where restoring proper Wnt signaling may support the repair of damaged tissues in conditions such as idiopathic pulmonary fibrosis.